Mene Pangalos, AstraZeneca EVP (via YouTube)

Covid-19 roundup: As­traZeneca may not file its vac­cine in the US; Iver­mectin fails to re­duce hos­pi­tal­iza­tions in large tri­al

As­traZeneca’s top re­searcher Mene Pan­ga­los sig­naled that the com­pa­ny may cut away from sub­mit­ting its Covid-19 vac­cine to the US FDA for ap­proval, cit­ing months of dis­cus­sions with the reg­u­la­tor.

“We don’t need to push it in places we are not need­ed or want­ed,” Pan­ga­los told the Fi­nan­cial Times on Thurs­day. “If we don’t end up sub­mit­ting it for a BLA [bi­o­log­ics li­cense ap­pli­ca­tion], I don’t think it will have an im­pact around the world.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.